6533b86efe1ef96bd12cbf07

RESEARCH PRODUCT

Predictors of insulin resistance in patients with obesity: a pilot study.

Mariusz StępieńMarek ParadowskiMaciej BanachRafał Nikodem WlazełRizzo ManfrediAnna StępieńJacek Rysz

subject

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyWaistAdipokinePilot ProjectsBody adiposity indexBody Mass IndexWaist–hip ratioInsulin resistanceInternal medicinemedicineHumansResistinObesityAgedAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinMiddle Agedmedicine.diseaseEndocrinologyC-Reactive ProteinResistinFemaleAdiponectinInsulin ResistanceCardiology and Cardiovascular Medicinebusinesscytokines inflammatory markers insulin resistance obesity obesity indicesBiomarkers

description

We compared adipokines and inflammatory markers in obese insulin-sensitive (group A, n = 16) and insulin-resistant (group B, n = 48) patients divided according to homeostasis model assessment of insulin resistance (HOMA-IR). Serum levels of adiponectin, leptin, resistin, high-sensitivity C-reactive protein, interleukin 6, and tumor necrosis factor α were measured. Weight, height, waist (WC) and hip circumferences, waist to hip ratio , weight to height ratio, visceral adiposity index (VAI), and body adiposity index (BAI) were measured. The WC and VAI were significantly higher in group B (113.9 ± 11.1 vs 105.3 ± 9.8cm; P < .01 and 2.3 ± 1.1 vs 1.6 ± 0.9; P < .05, respectively), while serum adiponectin levels were higher in group A (24.5 ± 14.6 vs 15.1 ± 9.6 ng/mL; P < .005). The BAI strongly correlated with adiponectin and leptin in group B ( r = .479; P < .001 and r = .705; P < .001). Insulin resistance is associated with visceral adiposity described by VAI and WC. The BAI may be a useful index in obese patients, especially with insulin resistance.

yearjournalcountryeditionlanguage
2012-12-26Angiology
10.1177/0003319712468291https://pubmed.ncbi.nlm.nih.gov/23267236